B2C
Day One Biopharmaceuticals
United Statesrethinkplgg.com
Day One Biopharmaceuticals develops new medicines targeting pediatric low-grade glioma (pLGG) and provides resources to assist families in managing diagnosis and treatment.
unknownseries-b
series-b
Stage
4
Funding Rounds
About
Day One Biopharmaceuticals develops new medicines targeting pediatric low-grade glioma (pLGG) and provides resources to assist families in managing diagnosis and treatment.
Explore Day One Biopharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.